Biocon, India's top biotech company, is looking to go in for listing of its stocks overseas in two years time, said its chairman and managing director Kiran Mazumdar-Shaw.
"Not immediately but we are looking for about a two-year timeframe (for overseas listing)," Mazumdar-Shaw told PTI in Bangalore.
She wouldn't say at this stage whether the Bangalore-based company would go in for listing on a US bourse or European.
"It would depend on a lot of factors. But obviously when biotech companies go for listing, they will go generally for US listing," Mazumdar-Shaw said. "Unless, we have some strategic reasons for doing it elsewhere (not in US)."
She said Biocon's bid to acquire the intellectual property assets of its research and development partner Nobex Corporation will take several months.
Nobex had recently taken shelter under Chapter 11 of US bankruptcy laws.
Based on progress made till date, Biocon does not anticipate any disruption to its ongoing oral insulin research programme, licensed from Nobex.
Biocon's investment in Nobex was $1 million in common stock and $4.8 million in convertible loans.
Mazumdar-Shaw said: "In the meantime {till Biocon is able to acquire IP (intellectual property) assets of Nobex}, we will just progress our other programmes that we have with them (Nobex) which we have been doing on our own for quite a few months."
Mazumdar-Shaw said Biocon is in discussions with US-based clinical trials major Scirex Corporation to off-load a "small", minority stake in the Bangalore-based firm's subsidiary Clinigene International.
"It (the deal) should happen in six months."
Mazumdar-Shaw also said her company has aggressive head-count ramp up plans both on the research and development, and the marketing sides.
"I would certainly say the headcount will go up significantly. Last year, we added close to 600 people. This year, we will add 600-700 people."
© 2026